Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 1:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 147 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety Evaluation of Escalating Doses Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects

NCT04583228
View directory record Official record
Conditions
COVID 19
Interventions
HLX71, Placebo
Drug · Other
Lead sponsor
Hengenix Biotech Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 7, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults

NCT00098098
View directory record Official record
Conditions
RECOMBINANT BOTULINUM VACCINE A/B
Interventions
rBV A/B
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 40 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 7, 2026, 1:26 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies

NCT02175433
View directory record Official record
Conditions
Relapsed Lymphoid Malignancy, Refractory Lymphoid Malignancy
Interventions
AGS67E
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
4
States / cities
Duarte, California • Stanford, California • Fairway, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 7, 2026, 1:26 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of TAK-828 Escalating Multiple-Doses in Healthy Participants

NCT02817516
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-828, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 7, 2026, 1:26 PM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas

NCT03188328
View directory record Official record
Conditions
Inoperable Solid Tumors or Lymphomas
Interventions
AvidinOX, 177Lu-ST2210
Drug
Lead sponsor
Alfasigma S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 7, 2026, 1:26 PM EDT
Completed Phase 1 Interventional

Redirected High Affinity Gag-Specific Autologous T Cells for HIV Gene Therapy

NCT00991224
View directory record Official record
Conditions
HIV Infections
Interventions
WT-gag-TCR modified T cells, α/6-gag-TCR modified T cells, STI or Drug Holiday
Biological · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 7, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults

NCT01172054
View directory record Official record
Conditions
Influenza
Interventions
VAX128, Placebo
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Oct 7, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V

NCT00097396
View directory record Official record
Conditions
Pneumonic Plague, Preventive Therapy
Interventions
rF1V vaccine
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Oct 7, 2026, 1:26 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of GNS561 in Patients With Liver Cancer

NCT03316222
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cholangiocarcinoma, Intrahepatic
Interventions
GNS561
Drug
Lead sponsor
Genoscience Pharma
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 7, 2026, 1:26 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 in Adults With Ischemic Heart Failure

NCT01082094
View directory record Official record
Conditions
Heart Failure
Interventions
ACRX-100
Biological
Lead sponsor
Juventas Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Birmingham, Alabama • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 7, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117

NCT03325595
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AEF0117, Placebo
Drug
Lead sponsor
Aelis Farma
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 7, 2026, 1:26 PM EDT
Not listed Phase 1 Interventional

Evaluation of Ascorbate-Meglumine Therapeutic for SRS

NCT06433791
View directory record Official record
Conditions
Safety
Interventions
Ascorbate-Meglumine
Drug
Lead sponsor
LadeRx LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 7, 2026, 1:26 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

First in Humans Study of JDTic

NCT01431586
View directory record Official record
Conditions
Cocaine Dependence
Interventions
JDtic
Drug
Lead sponsor
RTI International
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Oct 7, 2026, 1:26 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors

NCT01738451
View directory record Official record
Conditions
Cancer
Interventions
GSK2118436 75 mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Scottsdale, Arizona • Memphis, Tennessee • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 7, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes

NCT05925920
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2
Interventions
ENT-03, Placebo
Drug
Lead sponsor
Metabolics Pharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 7, 2026, 1:26 PM EDT
Completed Phase 1 Interventional

Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)

NCT00806208
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
MEDI-507, Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Timeline
1999 – 2000
U.S. locations
3
States / cities
St Louis, Missouri • Omaha, Nebraska • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2008 · Synced Oct 7, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects

NCT04999527
View directory record Official record
Conditions
Healthy Volunteer
Interventions
DISC-0974, Placebo
Drug
Lead sponsor
Disc Medicine, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 7, 2026, 1:26 PM EDT
Active, not recruiting Phase 1 Interventional

Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

NCT05657301
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
KH631
Drug
Lead sponsor
Chengdu Origen Biotechnology Co., Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Phoenix, Arizona • Lemont, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 7, 2026, 1:26 PM EDT
Completed Phase 1 Interventional

An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers

NCT00322127
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AMD3100
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 7, 2026, 1:26 PM EDT
Terminated Phase 2 Interventional Results available

A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity

NCT00712322
View directory record Official record
Conditions
Neurogenic Detrusor Overactivity
Interventions
Darifenacin
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
2 Years to 15 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
9
States / cities
San Diego, California • Boston, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 7, 2026, 1:26 PM EDT
Withdrawn Phase 2 Interventional

Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma

NCT01304628
View directory record Official record
Conditions
Asthma
Interventions
PL-3994
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cranbury, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Oct 7, 2026, 1:26 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium

NCT03049852
View directory record Official record
Conditions
Pterygium
Interventions
CBT-001 single dose, Vehicle, CBT-001 Multi-dose
Drug
Lead sponsor
Cloudbreak Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Laguna Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 7, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers

NCT02202187
View directory record Official record
Conditions
Infections, Respiratory Tract
Interventions
GSK2140944, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 7, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants

NCT02008279
View directory record Official record
Conditions
Healthy
Interventions
100 mg CNTO 3157, 300 mg CNTO 3157, 600 mg CNTO 3157, Placebo
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 7, 2026, 1:26 PM EDT